Publications by authors named "Shinobu Tamura"

Background: Vascular Ehlers-Danlos syndrome has a high mortality rate due to hemorrhagic complications.

Case Presentation: We report a case of vascular-type Ehlers-Danlos syndrome diagnosed due to rupture of multiple celiac aneurysms. The patient was a 25-year-old Japanese man with a history of a sigmoid perforation.

View Article and Find Full Text PDF

C-Mannosyl tryptophan (CMW), a unique glycosylated amino acid, is considered to be produced by degradation of C-mannosylated proteins in living organism. Although protein C-mannosylation is involved in the folding and secretion of substrate proteins, the pathophysiological function in the hematological system is still unclear. This study aimed to assess CMW in the human hematological disorders.

View Article and Find Full Text PDF

Schwannomatosis (SWN) is a rare genetic condition characterized by the risk of developing multiple benign peripheral nerve sheath tumors; however, the risk of developing malignant tumors in patients with SWN remains unclear. This study described the case of a 57-year-old Japanese man diagnosed with SWN whose older brother also had SWN. Whole-exome sequencing identified a heterozygous mutation [c.

View Article and Find Full Text PDF

Background: Multidrug chemotherapy for Ewing sarcoma can lead to severe myelosuppression. We proposed two clinical questions (CQ): CQ #1, "Does primary prophylaxis with G-CSF benefit chemotherapy for Ewing sarcoma?" and CQ #2, "Does G-CSF-based intensified chemotherapy improve Ewing sarcoma treatment outcomes?".

Methods: A comprehensive literature search was conducted in PubMed, Cochrane Library, and Ichushi web databases, including English and Japanese articles published from 1990 to 2019.

View Article and Find Full Text PDF

Introduction: Chemotherapy for breast cancer can cause neutropenia, increasing the risk of febrile neutropenia (FN) and serious infections. The use of granulocyte colony-stimulating factors (G-CSF) as primary prophylaxis has been explored to mitigate these risks. To evaluate the efficacy and safety of primary G-CSF prophylaxis in patients with invasive breast cancer undergoing chemotherapy.

View Article and Find Full Text PDF
Article Synopsis
  • G-CSF is a supportive treatment used to prevent severe complications from chemotherapy in patients with non-round cell soft tissue sarcomas (NRC-STS), with two key clinical questions raised about its effectiveness.
  • A literature review found a limited number of studies that addressed these questions, resulting in only a few articles being included for analysis.
  • The conclusion suggests that there is insufficient scientific evidence to confirm the benefits of G-CSF prophylaxis in improving treatment outcomes for NRC-STS, indicating the need for further research.
View Article and Find Full Text PDF
Article Synopsis
  • Relapsed or refractory acute myeloid leukemia (AML) has poor outcomes, and the impact of granulocyte colony-stimulating factor (G-CSF) combined with chemotherapy is still debated.
  • A systematic literature review and meta-analysis were conducted, assessing 11 studies, which suggested that G-CSF priming did not significantly improve response rates or overall survival for AML patients, although there was a slight trend towards lower relapse rates.
  • Certain groups, particularly those with intermediate cytogenetic risk and those receiving high-dose cytarabine, showed prolonged overall survival with G-CSF priming, indicating the need for further research to find the most suitable patients for this treatment approach.*
View Article and Find Full Text PDF

Background: Febrile neutropenia represents a critical oncologic emergency, and its management is pivotal in cancer therapy. In several guidelines, the use of granulocyte colony-stimulating factor (G-CSF) in patients with chemotherapy-induced febrile neutropenia is not routinely recommended except in high-risk cases. The Japan Society of Clinical Oncology has updated its clinical practice guidelines for the use of G-CSF, incorporating a systematic review to address this clinical question.

View Article and Find Full Text PDF
Article Synopsis
  • Granulocyte colony-stimulating factor (G-CSF) is used to prevent febrile neutropenia (FN) in cancer patients, with two types available in Japan: long-lasting PEG G-CSF and short-term non-PEG G-CSF.
  • A systematic review of studies found that PEG G-CSF significantly reduces the incidence of FN compared to non-PEG G-CSF, based on a thorough analysis of 23 articles.
  • The study concludes that a single dose of PEG G-CSF is preferred for primary prevention of FN, as it shows stronger evidence compared to multiple doses of non-PEG G-CSF.
View Article and Find Full Text PDF

Introduction: Pegcetacoplan, the first approved proximal complement C3 inhibitor, showed superiority to eculizumab in improving hemoglobin levels and clinical outcomes in the phase 3 PEGASUS study in patients with paroxysmal nocturnal hemoglobinuria (PNH) and inadequate response to eculizumab.

Methods: This analysis evaluates the efficacy and safety of pegcetacoplan for Japanese patients in PEGASUS, as they are known for different clinicopathologic features compared to non-Asian patients. Ten Japanese patients were enrolled to receive pegcetacoplan (n=5) or eculizumab (n=5) during the 16-week randomized controlled period.

View Article and Find Full Text PDF
Article Synopsis
  • Granulocyte colony-stimulating factor (G-CSF) is used to reduce the risk of neutropenia and infections during cancer chemotherapy, but its effectiveness for digestive system tumors is still uncertain.
  • A systematic review was conducted to evaluate the effectiveness of G-CSF as primary prophylaxis and its impact on the intensity of chemotherapy for various digestive system tumors.
  • The findings indicated that while G-CSF's use in colorectal cancer chemotherapy is inappropriate, there wasn't enough data to make strong recommendations for other types of digestive cancers.
View Article and Find Full Text PDF
Article Synopsis
  • The review examines the optimal timing for administering prophylactic pegylated granulocyte colony-stimulating factor (G-CSF) during cancer chemotherapy, focusing mainly on Day 2 versus Days 3-5.
  • Out of 300 studies initially reviewed, only four met the criteria, suggesting a potential increase in febrile neutropenia when G-CSF is given on Days 3-5 compared to Day 2, but no significant differences in overall survival or infection-related mortality were found.
  • The findings indicate weak recommendations for both timing options and emphasize the need for more research to make clearer guidelines for pegylated G-CSF administration.
View Article and Find Full Text PDF

Granulocyte colony-stimulating factor (G-CSF) decreases the incidence, duration, and severity of febrile neutropenia (FN); however, dose reduction or withdrawal is often preferred in the management of adverse events in the treatment of urothelial cancer. It is also important to maintain therapeutic intensity in order to control disease progression and thereby relieve symptoms, such as hematuria, infection, bleeding, and pain, as well as to prolong the survival. In this clinical question, we compared treatment with primary prophylactic administration of G-CSF to maintain therapeutic intensity with conventional standard therapy without G-CSF and examined the benefits and risks as major outcomes.

View Article and Find Full Text PDF

Febrile neutropenia (FN) is a major concern in patients undergoing chemotherapy for diffuse large B-cell lymphoma (DLBCL); however, the overall risk of FN is difficult to assess. This study aimed to develop a model for predicting the occurrence of FN in patients with DLBCL. In this multicenter, retrospective, observational analysis, a multivariate logistic regression model was used to analyze the association between FN incidence and pretreatment clinical factors.

View Article and Find Full Text PDF

Background: Granulocyte colony-stimulating factor (G-CSF) is commonly administered to cancer patients undergoing myelosuppressive chemotherapy, especially when incidence rate of febrile neutropenia (FN) surpasses 20%. While primary prophylaxis with G-CSF has been proven effective in preventing FN in patients with cancer, there is limited evidence regarding its efficacy in specifically, lung cancer. Our systematic review focused on the efficacy of G-CSF primary prophylaxis in lung cancer.

View Article and Find Full Text PDF

A 70-year-old Japanese woman with hypertension, dyslipidemia, and diabetes mellitus complained of abdominal discomfort and vomiting and was brought to our emergency department by ambulance two days later with impaired consciousness. Her vital signs suggested shock with a heart rate of 120 bpm. Electrocardiogram and initial transthoracic echocardiography suggested an inferior wall ST-elevation myocardial infarction, but the altered consciousness was inconsistent.

View Article and Find Full Text PDF

We report a case of a 24-year-old man who developed angioimmunoblastic T-cell lymphoma (AITL) after treatment for refractory lymphocyte-rich classic Hodgkin lymphoma (LR-CHL). This patient was treated with the BV+AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) protocol for LR-CHL but progressed before completing chemotherapy. The pathological imaging showed the typical findings of LR-CHL at the first onset and first progression.

View Article and Find Full Text PDF
Article Synopsis
  • * This study examined the effects of CD47 and SIRPα in 84 myeloid sarcoma biopsy samples, classifying patients based on whether SIRPα was present in tumor cells (nSIRPα) or surrounding stromal cells (miSIRPα).
  • * Patients with CD47-positive tumors experienced better overall survival rates and greater lymphocytic infiltration, marking a new finding that suggests CD47 may have a protective role in myeloid sarcoma, although further studies on genetic factors
View Article and Find Full Text PDF

: The Wakayama prefecture is endemic for two types of tick-borne rickettsioses: Japanese spotted fever (JFS) and scrub typhus (ST). Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne hemorrhagic viral disease with a high mortality rate and is often difficult to differentiate from such rickettsioses. SFTS cases have recently increased in Wakayama prefecture.

View Article and Find Full Text PDF

Patients with acute myeloid leukemia (AML) who have comorbidities have limited treatment options, thereby resulting in poor prognosis. Venetoclax, a specific B-cell lymphoma-2 inhibitor, has recently been approved for AML in combination with hypomethylating agents; however, only one report has described its use in patients undergoing dialysis. Herein, we report the effectiveness of combined venetoclax and azacitidine in a 73-year-old man with AML undergoing dialysis and who was ineligible for standard therapies.

View Article and Find Full Text PDF

Neutralizing antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being developed world over. We investigated the possibility of producing artificial antibodies from the formalin fixation and paraffin-embedding (FFPE) lung lobes of a patient who died by coronavirus disease 2019 (COVID-19). The B-cell receptors repertoire in the lung tissue where SARS-CoV-2 was detected were considered to have highly sensitive virus-neutralizing activity, and artificial antibodies were produced by combining the most frequently detected heavy and light chains.

View Article and Find Full Text PDF

Objectives: Graves' disease (GD) has been highlighted as a possible adverse effect of the respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine. However, it is unknown if the SARS-CoV-2 vaccine disrupts thyroid autoimmunity. We aimed to present long-term follow-up of thyroid autoimmunity after the SARS-CoV-2 BNT162b2 mRNA vaccine.

View Article and Find Full Text PDF